Evidence map›Paper›PMID 40897389›Full record

ArticleDrug testing and analysis2025

Identification of Tetrahydrocannabidiol Metabolites in Human Urine.

Willi Schirmer, Isabelle Mösch, Stefan Schürch, Wolfgang Weinmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Willi SchirmerInstitute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0009-0004-5579-2217
Isabelle MöschInstitute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0009-0002-7890-2162
Stefan SchürchDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-5109-4623
Wolfgang WeinmannInstitute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-8659-1304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tetrahydrocannabidiol (H4CBD) is an emerging semisynthetic cannabinoid, which has been known since 1940. Like hexahydrocannabinol (HHC), it is easily obtained by hydrogenation of available phytocannabinoids, in the case of H4CBD by hydrogenation of cannabidiol (CBD). H4CBD shows a weak affinity for the CB

Indexed as

CannabidiolSubstance Abuse DetectionChromatography, LiquidGas Chromatography-Mass SpectrometryHumansHydroxylationTandem Mass SpectrometryCannabidiol

Identifiers

PMID40897389
PMCPMC12689245

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.